Want to see FR:SIGHT full AI Analyst Report?
SIGHT Stock Chart & Stats
€0.12
<€0.01(0.12%)
At close: 4:00 PM EDT
€0.12
<€0.01(0.12%)
Day’s Range― - ―
52-Week Range€0.07 - €0.24
Previous CloseN/A
Volume185.13K
Average Volume (3M)1.83M
Market Cap
€17.67M
Enterprise Value€29.15M
Total Cash (Recent Filing)€1.67M
Total Debt (Recent Filing)€12.84M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Mar 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding237,641,720
10 Day Avg. Volume2,273,457
30 Day Avg. Volume1,826,045
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.62
Price to Sales (P/S)15482.52
P/FCF Ratio-1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.08Price Target Upside-33.33% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.22
Revenue Forecast (FY)€11.20M
Bulls Say, Bears Say
Bulls Say
Debt ReductionLower debt reduces financing pressure and represents a concrete improvement in the capital structure. Although solvency remains constrained, debt reduction can preserve more future cash for clinical development and may improve financial flexibility if sustained over coming periods.
Improving Cash BurnThe narrower operating cash outflow indicates some progress in controlling cash consumption, even though the company remains cash-burning. Continued improvement would extend available funding and reduce the pace at which external capital is needed to support development.
Focused Ophthalmology PipelineA focused therapeutic strategy in severe retinal disease gives GenSight a clear scientific and commercial identity. Concentration on gene therapy and optogenetics may help align research resources around differentiated treatments for patients with substantial unmet medical needs.
Bears Say
Revenue CollapseThe extreme revenue decline highlights limited commercial scale and makes near-term operating performance highly dependent on development progress or future financing. Such volatility weakens revenue visibility and reduces the company’s ability to fund operations through internally generated sales.
Persistent LossesRecurring operating and net losses show that the business has not reached breakeven and continues to consume resources while pursuing development. Persistent losses can constrain strategic options and require ongoing access to financing before products generate meaningful commercial revenue.
Negative Equity And Funding DependenceNegative shareholders’ equity is a durable solvency warning because liabilities exceed the recorded equity base. Combined with reliance on external funding, it limits financial resilience and leaves the company more exposed to refinancing or dilution risk as development spending continues.
GenSight Biologics SA News
SIGHT FAQ
What was GenSight Biologics SA’s price range in the past 12 months?
GenSight Biologics SA lowest stock price was €0.07 and its highest was €0.24 in the past 12 months.
What is GenSight Biologics SA’s market cap?
GenSight Biologics SA’s market cap is €17.67M.
When is GenSight Biologics SA’s upcoming earnings report date?
GenSight Biologics SA’s upcoming earnings report date is Mar 19, 2027 which is in 157 days.
How were GenSight Biologics SA’s earnings last quarter?
GenSight Biologics SA released its earnings results on Sep 29, 2026. The company reported -€0.05 earnings per share for the quarter.
Is GenSight Biologics SA overvalued?
According to Wall Street analysts GenSight Biologics SA’s price is currently Overvalued.
Does GenSight Biologics SA pay dividends?
GenSight Biologics SA does not currently pay dividends.
What is GenSight Biologics SA’s EPS estimate?
GenSight Biologics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GenSight Biologics SA have?
GenSight Biologics SA has 237,641,720 shares outstanding.
What happened to GenSight Biologics SA’s price movement after its last earnings report?
GenSight Biologics SA reported an EPS of -€0.05 in its last earnings report. Following the earnings report the stock price went down -12.389%.
Which hedge fund is a major shareholder of GenSight Biologics SA?
Currently, no hedge funds are holding shares in FR:SIGHT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GenSight Biologics SA
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
SIGHT Stock 12 Month Forecast
Average Price Target
€0.08
▼(-33.33% Downside)